The Summary
In a secondary analysis of the randomized STEP UP trial, researchers used MRI scans to evaluate 55 adults with obesity receiving weekly semaglutide or a placebo over 72 weeks. Participants taking semaglutide experienced significant reductions in total body fat, visceral adipose tissue, and thigh muscle fat infiltration compared to placebo. Although minor decreases in skeletal muscle volume were observed, functional performance was preserved, with participants maintaining their baseline sit-to-stand repetitions. The data indicate that semaglutide reduces intramuscular fat without compromising basic muscular performance.
Why this is interesting
Widespread concern surrounds whether GLP-1 medications cause unhealthy muscle loss. This study provides critical nuance by showing that while overall muscle volume drops slightly, muscle quality actually improves through reduced fat infiltration. Crucially, real-world physical capability—measured by sit-to-stand tests—did not decline. For individuals utilizing these treatments, these findings suggest that the drop in lean tissue may largely reflect healthy remodeling rather than debilitating weakness, offering reassurance that functional vitality remains intact.